Thank you, Madam Chairperson.
I want to come back to the issue of independence in decision-making, because I didn't get a chance to hear a comment from everyone and I just want to go through it again.
Everything I've read on this whole issue points to dealing first with the secrecy that surrounds the whole drug approval process. We can extend that pre-market approval process now to the post-market surveillance issue. How do we best do that? How do we ensure that all decisions relating to clinical trials and to adverse reactions are available to the academic community, so that they can address these issues and advance the concerns, and available to the public, who are looking for some wisdom as they make these difficult decisions?